This study shows that an abnormal karyotype is present in approximately one third of SMF and confers a more advanced clinical phenotype. Patients with monosomal karyotype have poor survival independently from the MYSEC-PM risk stratification and need to be identified. These findings reinforce the utility of assessing cytogenetics in SMF.
File in questo prodotto:
Non ci sono file associati a questo prodotto.